GNCAUnknown
GENOCEA BIOSCIENCES, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for GENOCEA BIOSCIENCES, INC. (GNCA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are GNCA insiders buying or selling?
GENOCEA BIOSCIENCES, INC. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 66 Form 4 filings for GNCA: 38 buys ($241.9M) and 28 sells ($6.8M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Jun 3, 2022)
Total Form 4 filings
66
SEC EDGAR
Insider filers
22
Insider buys (38)
$241.9M
Insider sells (28)
$6.8M
Insider sentiment
Net buyingNet insider flow of $235.1M in net buying since January 2018.
Recent GNCA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 3, 2022 | Diantha Duvall | CHIEF FINANCIAL OFFICER | Sale | 1.4K | $0.06 | $81.3 | SEC ↗ |
| Jun 3, 2022 | Jessica Baker Flechtner | Chief Scientific Officer | Sale | 1.6K | $0.06 | $94.68 | SEC ↗ |
| Jun 3, 2022 | William D Clark | President and CEO | Sale | 4.0K | $0.06 | $241.38 | SEC ↗ |
| Jun 2, 2022 | Jacquelyn L Sumer | CHIEF LEGAL & COMPLIANCE OFF | Sale | 2.5K | $0.06 | $150.25 | SEC ↗ |
| Jun 2, 2022 | William D Clark | President and CEO | Sale | 117.2K | $0.06 | $7.2K | SEC ↗ |
| Jun 1, 2022 | George Siber | Director | Sale | 20.4K | $0.07 | $1.3K | SEC ↗ |
| May 26, 2022 | Paul Edward Walker | 10% Owner | Sale | 10.4M | $0.07 | $750.7K | SEC ↗ |
| May 26, 2022 | Peter W. Sonsini | 10% Owner | Sale | 10.4M | $0.07 | $750.7K | SEC ↗ |
| May 26, 2022 | Scott D Sandell | 10% Owner | Sale | 10.4M | $0.07 | $750.7K | SEC ↗ |
| May 26, 2022 | New Enterprise Associates 16, L.P. | 10% Owner | Sale | 10.4M | $0.07 | $750.7K | SEC ↗ |
| May 26, 2022 | Mohamad Makhzoumi | 10% Owner | Sale | 10.4M | $0.07 | $750.7K | SEC ↗ |
| May 26, 2022 | Anthony A. Florence Jr. | 10% Owner | Sale | 10.4M | $0.07 | $750.7K | SEC ↗ |
| May 26, 2022 | Carmen Chang | 10% Owner | Sale | 10.4M | $0.07 | $750.7K | SEC ↗ |
| May 26, 2022 | Ali Behbahani | Director, 10% Owner | Sale | 10.4M | $0.07 | $750.7K | SEC ↗ |
| May 26, 2022 | Forest Baskett | 10% Owner | Sale | 10.4M | $0.07 | $750.7K | SEC ↗ |
| May 26, 2022 | Raymond D Stapleton JR | CHIEF TECHNOLOGY OFFICER | Sale | 2.5K | $0.09 | $222.5 | SEC ↗ |
| May 26, 2022 | Jessica Baker Flechtner | Chief Scientific Officer | Sale | 16.5K | $0.09 | $1.5K | SEC ↗ |
| May 26, 2022 | Diantha Duvall | CHIEF FINANCIAL OFFICER | Sale | 24.4K | $0.08 | $1.9K | SEC ↗ |
| Apr 5, 2022 | Jessica Baker Flechtner | Chief Scientific Officer | Sale | 1.2K | $1.25 | $1.5K | SEC ↗ |
| Apr 5, 2022 | Diantha Duvall | CHIEF FINANCIAL OFFICER | Sale | 963 | $1.25 | $1.2K | SEC ↗ |
| Apr 5, 2022 | Thomas Andrew Davis | CHIEF MEDICAL OFFICER | Sale | 1.1K | $1.25 | $1.4K | SEC ↗ |
| Apr 5, 2022 | William D Clark | President and CEO | Sale | 3.9K | $1.25 | $4.9K | SEC ↗ |
| Apr 5, 2022 | Girish N Aakalu | CHIEF BUSINESS OFFICER | Sale | 963 | $1.25 | $1.2K | SEC ↗ |
| Mar 17, 2022 | Jessica Baker Flechtner | Chief Scientific Officer | Sale | 3.3K | $1.10 | $3.7K | SEC ↗ |
| Mar 17, 2022 | Diantha Duvall | CHIEF FINANCIAL OFFICER | Sale | 2.9K | $1.10 | $3.2K | SEC ↗ |
Showing the 25 most recent of 66 Form 4 filings for GENOCEA BIOSCIENCES, INC..
Most active GNCA insiders
- William D Clark6 filings
- Ali Behbahani4 filings
- Anthony A. Florence Jr.4 filings
- Carmen Chang4 filings
- Diantha Duvall4 filings
Ask anything about GNCA insider activity
Use Trabud's AI agent to query GENOCEA BIOSCIENCES, INC.'s Form 4 history in plain English — "Show me GNCA CEO purchases this year" or compare it against any other ticker.
Open the AI agentGNCA insider trading FAQ
Are GENOCEA BIOSCIENCES, INC. insiders buying or selling?
GENOCEA BIOSCIENCES, INC. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 66 Form 4 filings for GNCA: 38 buys ($241.9M) and 28 sells ($6.8M). Over the full record that is net buying of $235.1M.
How many insiders trade GNCA stock?
22 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for GENOCEA BIOSCIENCES, INC.. The most recent filing was accepted on Jun 3, 2022.
Where does Trabud get GNCA insider trading data?
All GNCA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.